Pfizer obesity treatment has become a significant topic in the pharmaceutical industry as the company terminates the development of danuglipron, a once-promising oral obesity medication.Following a substantial phase three trial, which is the final hurdle before regulatory approval, Pfizer halted studies after a participant experienced a case of liver injury linked to the drug.